Orviglance meets the primary endpoint in the SPARKLE study with a p-value of
Redeye adjusts its estimates ahead of Arise’s Q1 report, which is due next week on 7 May.
On the right track after a challenging 2023 Positive revisions, 10% EBIT margins looks achievable We...
STENOCARE published on May 2 the company’s Q1-report for 2024, showing progress.
Redeye briefly comments on Enviro’s press release, which stated that Enviro has received a second pa...
Omsättningen steg kraftigt efter att iZafe levererat 1000 enheter till Nederländerna.
Q1 rapporten kom in något sämre än Analysguidens prognos och marknaden reagerade surt på rapporten o...
Q1 var utmanande med svag efterfrågan och omsättningen minskade.
Redeye presents its preview for Devyser’s Q1 2024 report, which is due on May 8.
Cardeon AB (publ) (”Cardeon” eller ”Bolaget”) är ett investmentbolag som investerar i innovativa för...
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest An...
Organic growth of 11% vs. cons. 10% Adj. EBITA SEK 128m, 13% below consensus Gross margin recovery i...
Slutlig studiedesign närmar sig Medivir har fullt fokus på att ta fostrox framåt mot en registrering...
MTI Investment SE (”MTI” eller ”Bolaget”) meddelade den 30 april 2024 att Bolaget, genom dotterbolag...
Tallinna Sadam's y/y decline in total cargo volumes ended in Q1 after persisting for nine quarters.
Q1: Clean EBIT of SEK 5m, production issues Pulp prices move higher, demand stronger Fair value rang...
Q1'24 results due 7 May '24e-'26e EBIT up 0.8-1.6% due to FX 29-39% below historical NTM P/E and NTM...
GC&MP outperforms, NW&FT takes a breather, FW lags behind Sales decline, but EBIT and cash flow bett...
The company writes down EUR 6m receivable which will have a corresponding negative impact on the EBI...
Redeye endorses that CLS’ partner, ClearPoint Neuro, has received FDA (510k) clearance for its Prism...
